|
12 Sep 2025 |
Lupin
|
Consensus Share Price Target
|
2040.80 |
2224.81 |
- |
9.02 |
buy
|
|
|
|
|
23 Jun 2023
|
Lupin
|
Sharekhan
|
2040.80
|
779.00
|
874.00
(133.50%)
|
|
Sell
|
|
|
|
|
22 Jun 2023
|
Lupin
|
ICICI Securities Limited
|
2040.80
|
740.00
|
875.05
(133.22%)
|
|
Sell
|
|
|
Lupin is the first company globally to receive the final approval of the USFDA for US$1.264bn inhalation drug gSpiriva (Tiotropium Bromide). We factor in US$100mn revenue from this drug in FY24E.
|
|
21 Jun 2023
|
Lupin
|
Axis Direct
|
2040.80
|
950.00
|
875.05
(133.22%)
|
Target met |
Buy
|
|
|
We believe both these products could increase the gross margins by 100 bps in next two years. We have increased our target price to Rs 950 (from Rs 825) with Buy recommendations.
|
|
16 May 2023
|
Lupin
|
Geojit BNP Paribas
|
2040.80
|
830.00
|
790.75
(158.08%)
|
Target met |
Hold
|
|
|
|
|
11 May 2023
|
Lupin
|
ICICI Direct
|
2040.80
|
740.00
|
765.45
(166.61%)
|
|
Hold
|
|
|
|
|
11 May 2023
|
Lupin
|
Axis Direct
|
2040.80
|
825.00
|
765.45
(166.61%)
|
Target met |
Buy
|
|
|
We get more confidence in Lupin's business due to the following factors 1.) New launches in the US market like Darunavir, Cynocobalamin, Diazepem Gel, Vereniciline, Bromfenac, etc. excl. gSpirva We have BUY Rating on the stock
|
|
11 May 2023
|
Lupin
|
Motilal Oswal
|
2040.80
|
640.00
|
765.45
(166.61%)
|
|
Sell
|
|
|
|
|
10 May 2023
|
Lupin
|
Prabhudas Lilladhar
|
2040.80
|
730.00
|
750.20
(172.03%)
|
|
Hold
|
|
|
|
|
14 Feb 2023
|
Lupin
|
Axis Direct
|
2040.80
|
735.00
|
663.00
(207.81%)
|
Target met |
Hold
|
|
|
Recommendation: We maintain HOLD on stock
|
|
13 Feb 2023
|
Lupin
|
ICICI Securities Limited
|
2040.80
|
634.00
|
675.15
(202.27%)
|
Target met |
Sell
|
|
|
Lupin’s Q3FY23 performance was a beat on revenue front led by better than expected US sales. Revenue grew 3.9% YoY and 4.3% QoQ to Rs43.2bn (I-Sec: Rs41.4bn). US revenue was up 11.3% QoQ at US$177mn (I-Sec:US$172mn) led by new product launches (~US$20mn) and benefit from flu season.
|